| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.35B | 1.35B | 1.27B | 1.30B | 1.25B | 1.28B |
| Gross Profit | 1.19B | 1.19B | 1.13B | 1.15B | 1.11B | 1.15B |
| EBITDA | 387.80M | 378.56M | 399.81M | 345.57M | 318.89M | 450.37M |
| Net Income | 255.02M | 255.02M | 261.82M | 200.66M | 184.09M | 310.23M |
Balance Sheet | ||||||
| Total Assets | 3.23B | 3.23B | 3.13B | 2.99B | 2.70B | 3.12B |
| Cash, Cash Equivalents and Short-Term Investments | 702.60M | 702.60M | 577.75M | 957.11M | 817.58M | 1.27B |
| Total Debt | 38.88M | 38.88M | 46.99M | 50.65M | 50.94M | 72.12M |
| Total Liabilities | 595.81M | 595.81M | 643.72M | 622.38M | 451.15M | 518.66M |
| Stockholders Equity | 2.62B | 2.62B | 2.48B | 2.36B | 2.25B | 2.60B |
Cash Flow | ||||||
| Free Cash Flow | 430.26M | 430.26M | 297.25M | 336.74M | 259.12M | 393.30M |
| Operating Cash Flow | 472.20M | 472.20M | 327.25M | 367.08M | 318.58M | 447.75M |
| Investing Cash Flow | -10.59M | -10.59M | -286.29M | 54.21M | -295.94M | -44.91M |
| Financing Cash Flow | -247.24M | -247.24M | -287.81M | -236.81M | -610.56M | -252.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $165.32B | 21.94 | 25.82% | 2.28% | 7.36% | 6.18% | |
80 Outperform | $27.08B | 29.67 | 38.21% | 1.56% | 8.57% | 35.02% | |
80 Outperform | $38.96B | 18.71 | 14.50% | 1.54% | 7.44% | -4.57% | |
76 Outperform | $74.62B | 22.90 | 29.15% | 2.65% | 4.62% | 1.06% | |
74 Outperform | $6.40B | 25.61 | 10.00% | 2.01% | 5.92% | -2.98% | |
67 Neutral | $16.56B | 20.14 | 109.26% | ― | 5.24% | -16.05% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
On November 18, 2025, Dolby Laboratories announced its financial results for the fourth quarter and fiscal year 2025, reporting a total revenue of $307 million for the quarter and $1.35 billion for the year. The company highlighted growth in its Dolby Atmos and Dolby Vision technologies, as well as new partnerships and product launches, indicating a strong market position as it heads into fiscal year 2026.
On November 11, 2025, Dolby Laboratories‘ Compensation Committee approved the 2026 Executive Bonus Plan, targeting executive officers with bonuses based on a percentage of their base salary. The plan emphasizes achieving non-GAAP operating income and revenue goals, with potential adjustments by the Committee, impacting the final bonus amounts for executives.